News for SpringWorks Therapeutics, Inc. (SWTX)

Bank of America has revised its price target for SpringWorks Therapeutics (SWTX), reducing it from $87 to $84 while maintaining a Buy rating on the company's sh

Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See why SWTX is a good speculative “Buy”.

On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc.

Investors with a lot of money to spend have taken a bearish stance on SpringWorks Therapeutics SWTX. And retail traders should know. We noticed this today whe...

The following slide deck was published by SpringWorks Therapeutics, Inc.

As of Feb. 20, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading ...

SpringWorks Therapeutics (SWTX) jumped in premarket trading after the firm canceled its previously scheduled conf call.

SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of -44.44% and 2.52%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

SpringWorks Therapeutics reports FY GAAP EPS of -$3.48, missing estimates by $0.43, while revenue surges 3415.4% Y/Y to $191.59M, beating by $0.74M.

**media[542660]**

SpringWorks Therapeutics (SWTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving SpringWorks Therapeutics Inc (SWTX). The firm redu

SpringWorks Therapeutics (SWTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

On February 10, 2025, Badreddin Edris, Chief Operating Officer of SpringWorks Therapeutics Inc (SWTX), sold 30,000 shares of the company. Following this transac

On February 10, 2025, Saqib Islam, the Chief Executive Officer of SpringWorks Therapeutics Inc (SWTX), sold 48,000 shares of the company. Following this transac

**media[538234,538235,538236,538237,538238]**

**media[538164,538165,538166,538167,538168]**